OMNIPRED Drug Patent Profile
✉ Email this page to a colleague
When do Omnipred patents expire, and when can generic versions of Omnipred launch?
Omnipred is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in OMNIPRED is prednisolone acetate. There are eighty-eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the prednisolone acetate profile page.
Summary for OMNIPRED
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 74 |
Clinical Trials: | 3 |
Patent Applications: | 4,289 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in OMNIPRED? | OMNIPRED excipients list |
DailyMed Link: | OMNIPRED at DailyMed |
Recent Clinical Trials for OMNIPRED
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oregon Health and Science University | Phase 4 |
University of California, San Francisco | Phase 4 |
Winston Chamberlain, MD, PhD | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for OMNIPRED
US Patents and Regulatory Information for OMNIPRED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | OMNIPRED | prednisolone acetate | SUSPENSION/DROPS;OPHTHALMIC | 017469-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |